RANK and/or RANKL expression previously associated with poor clinical outcome in gastric cancer [24], acute myeloid leukaemia [25], breast cancer [26,27], (clear-cell) renal cell carcinoma [28,29], prostate cancer [30] and osteosarcoma [31]. Here, TNFSF11 is linked to prostate cancer.